Page last updated: 2024-10-27

fentanyl and Dysphagia

fentanyl has been researched along with Dysphagia in 6 studies

Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)
fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.

Research Excerpts

ExcerptRelevanceReference
"Failure to recognize the impact of various situations described throughout this work, including the bioavailability due to loss of oral route, due to pharmacokinetics and pharmacodynamics of the various drugs, either in the context of the impaired metabolism or excretion, or in due to pharmacological interactions, conditions a serious risk of subtreatment of pain and consequent impact in terms of quality of life."2.61[Opioids for Cancer Pain and its Use under Particular Conditions: A Narrative Review]. ( Brás, M; Fragoso, M; Vieira, C, 2019)
" Eighty per cent of patients were not asked about their ability to swallow solid, oral dosage forms by their physician."1.40Challenges of treating patients with chronic pain with dysphagia (CPD): physician and patient perspectives. ( Carlson, DR; Kopecky, EA; Nalamachu, S; Pergolizzi, JV; Raffa, RB; Taylor, R; Varanasi, RK, 2014)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's2 (33.33)29.6817
2010's2 (33.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Balko, RA1
Katzka, DA1
Murray, JA1
Alexander, JA1
Mara, KC1
Ravi, K1
Vieira, C1
Brás, M1
Fragoso, M1
Pergolizzi, JV1
Taylor, R1
Nalamachu, S1
Raffa, RB1
Carlson, DR1
Varanasi, RK1
Kopecky, EA1
Kuczkowski, KM1
Goldsworthy, M1
Smiley, RM1
Moore, RP1
Currier, DS1
Levin, KR1
Campbell, C1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Use of Xtampza ER to Overcome Difficulties in Swallowing Opioid Pills[NCT03588806]Phase 411 participants (Actual)Interventional2018-05-01Terminated (stopped due to Study halted permanently and will not resume; participants are no longer being examined or receiving intervention.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Pill Swallowing Difficulty Score

"Pill swallowing difficulty will be measured via a 0-10 scale with 0 being no trouble at all and 10 being the greatest difficulty possible. Responses will be summarized as change from baseline scores to the end of the study at clinic visit 4 (week 6)." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study. Baseline covers current opioid medication, and week 6 covers Xtampza ER.

Interventionunits on a scale (Mean)
Xtampza ER (Oxycodone) Treatment-5.7

Effect of Xtampza ER Conversion on Pain Intensity in the Last 24 Hours

"Percent change in pain intensity (in the last 24 hours) from baseline to the end of the study averaged over the last 7 days before clinic visit 4 (week 6). Pain Intensity is measured on a 0-10 scale, with 0 meaning no pain and 10 meaning the worst pain imaginable. As decreases in pain intensity are a sign of improvement, percent change in pain intensity is calculated as -(end of study - baseline)/baseline score." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study

Interventionpercent change (Mean)
Xtampza ER (Oxycodone) Treatment12.5

Effect of Xtampza ER Conversion on Pain Intensity in the Last 7 Days

"Percent change in pain intensity (in the past 7 days) from baseline to the end of the study at clinic visit 4 (week 6). Pain Intensity is measured on a 0-10 scale, with 0 meaning no pain and 10 meaning the worst pain imaginable. As decreases in pain intensity are a sign of improvement, percent change in pain intensity is calculated as -(end of study - baseline)/baseline score." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study

Interventionpercent change (Mean)
Xtampza ER (Oxycodone) Treatment9.3

Opioid Medication Satisfaction

"Opioid medication satisfaction will be measured via a 0-10 scale with 0 being not satisfied at all and 10 being completely satisfied. Responses will be summarized as change from baseline score to the end of the study at clinic visit 4 (week 6)." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study. Recorded baseline for current opioid medication and in week 6 for Xtampza ER.

Interventionunits on a scale (Mean)
Xtampza ER (Oxycodone) Treatment2.8

Patient Global Impression of Change (PGIC)

The subject's impression of the impact of the treatment on their pain and function will be measured with a 7-item scale (-3 = very much worse, -2 = much worse, -1 = minimally worse, 0 = no change, 1 = minimally improved, 2 = much improved, 3 = very much improved). Responses will be summarized as individual mean scores at clinic visit 4 (week 6). (NCT03588806)
Timeframe: Recorded in week 6.

Interventionunits on a scale (Mean)
Xtampza ER (Oxycodone) Treatment1.2

Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference

"The Pain Interference questions (#25-28) from the PROMIS-29 Adult Profile v2.0. Questions are measured on a 5-point scale with 1 being Not at all and 5 being Very much. Responses will be summed and converted to T-Scores using the Assessment Center PROMIS Scoring Service (www.assessmentcenter.net), which rescales the raw score to a standardized T-Score with a population mean of 50 and standard deviation of 10. Pain Interference T-Scores will be summarized as the change from baseline scores to the end of the study at clinic visit 4 (week 6)." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study

InterventionT-Score (Mean)
Xtampza ER (Oxycodone) Treatment-3.6

PROMIS Physical Function

"The Physical Function questions (#1-4) from the PROMIS-29 Adult Profile v2.0. Questions are measured on a 5-point scale with 5 being Without any difficulty and 1 being Unable to do. Responses will be summed and converted to T-Scores using the Assessment Center PROMIS Scoring Service (www.assessmentcenter.net), which rescales the raw score to a standardized T-Score with a population mean of 50 and standard deviation of 10. Physical Function T-Scores will be summarized as change from baseline score to the end of the study at clinic visit 4 (week 6)." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study

InterventionT-Score (Mean)
Xtampza ER (Oxycodone) Treatment0.7

PROMIS Depression, Anxiety, Satisfaction With Social Roles, and Sleep Disturbance

"The Depression (#9-12), Anxiety (#5-8), Satisfaction with Social Roles (#21-24), and Sleep Disturbance (#17-20) questions from the PROMIS-29 Adult Profile v2.0. Questions are measured on a 5-point scale with 1 being Never and 5 being Always. Responses for each section will be summed and converted to T-Scores using the Assessment Center PROMIS Scoring Service (www.assessmentcenter.net), which rescales the raw score to a standardized T-Score with a population mean of 50 and standard deviation of 10. These T-Scores will be summarized as change from baseline scores to the end of the study at clinic visit 4 (week 6)." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study

InterventionT-Score (Mean)
DepressionAnxietySatisfaction with Social RolesSleep Disturbance
Xtampza ER (Oxycodone) Treatment-0.4-1.71.1-3.7

Reviews

1 review available for fentanyl and Dysphagia

ArticleYear
[Opioids for Cancer Pain and its Use under Particular Conditions: A Narrative Review].
    Acta medica portuguesa, 2019, May-31, Volume: 32, Issue:5

    Topics: Administration, Oral; Analgesics, Opioid; Buprenorphine; Cancer Pain; Codeine; Deglutition Disorders

2019

Other Studies

5 other studies available for fentanyl and Dysphagia

ArticleYear
Same-day opioid administration in opiate naïve patients is not associated with opioid-induced esophageal dysfunction (OIED).
    Neurogastroenterology and motility, 2021, Volume: 33, Issue:5

    Topics: Adult; Aged; Analgesics, Opioid; Anesthetics, Intravenous; Chest Pain; Conscious Sedation; Deglutiti

2021
Challenges of treating patients with chronic pain with dysphagia (CPD): physician and patient perspectives.
    Current medical research and opinion, 2014, Volume: 30, Issue:2

    Topics: Analgesics, Opioid; Child; Chronic Pain; Data Collection; Deglutition Disorders; Fentanyl; Humans; M

2014
Transient aphonia and aphagia in a parturient after induction of combined spinal-epidural labor analgesia with subarachnoid fentanyl and bupivacaine.
    Acta anaesthesiologica Belgica, 2003, Volume: 54, Issue:2

    Topics: Adjuvants, Anesthesia; Adult; Analgesia, Epidural; Analgesia, Obstetrical; Anesthetics, Local; Aphon

2003
Loss of gag reflex and swallowing ability after administration of intrathecal fentanyl.
    Anesthesiology, 2007, Volume: 106, Issue:6

    Topics: Adult; Analgesia, Obstetrical; Analgesics, Opioid; Deglutition Disorders; Female; Fentanyl; Gagging;

2007
Dysphagia with intrathecal fentanyl.
    Anesthesiology, 1997, Volume: 87, Issue:6

    Topics: Adult; Analgesia, Obstetrical; Analgesics, Opioid; Bupivacaine; Deglutition Disorders; Female; Fenta

1997